Comment from The Geneva Foundation, HHS-OPHS-2018-0021, HHS-OPHS-2018-0021-0001, N/A
The Geneva FoundationOtherOther
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation (MGL-3196-11) / WRNMMC